Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Hold” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $80.60.

Several research analysts have recently commented on PBH shares. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group cut their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. The trade was a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its position in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after purchasing an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Prestige Consumer Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after purchasing an additional 1,289 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the last quarter. Jane Street Group LLC grew its stake in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after buying an additional 70,330 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its position in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $65.53 on Wednesday. The company has a market cap of $3.10 billion, a PE ratio of 17.34, a P/E/G ratio of 2.08 and a beta of 0.41. The firm’s 50 day moving average price is $65.97 and its 200-day moving average price is $63.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. Prestige Consumer Healthcare has a 52-week low of $57.25 and a 52-week high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business’s quarterly revenue was down 2.4% on a year-over-year basis. During the same period last year, the firm earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).